Baxter (NYSE:BAX) said yesterday that it launched an FDA-cleared clinical trial of its on-demand peritoneal dialysis solution generation system intended to allow patients to make peritoneal dialysis solutions in small batches at home.
The system is designed to use a small water filtration device, concentrates and Deerfield, Ill.-based Baxter’s Amia automated peritoneal dialysis system to turn a patient’s tap water into dialysis solution as needed for therapy sessions.
Baxter said that it has enrolled the first patient in the trial, which looks to assess the efficacy and safety of the new system for participants over 12 weeks. The company said it hopes to use data from the trial to support a New Drug Application for the concentrates and 510(k) clearance for the device.
“We are on a journey to transform how kidney disease is identified, managed and treated, with a focus on improving outcomes for patients. Our on-demand technology is the cornerstone of our innovation pipeline, as we believe the technology will open up new possibilities for therapy delivery while improving the experience for patients today,” renal care biz GM Laura Angelini said in a press release.
In November, Baxter said that it expanded its share purchase program to $3.4 billion.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.